{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015344","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.453452+00:00","generated_at":"2026-06-03T15:51:27.507665+00:00","sec_items":["3.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioxytran creates insider-only convertible preferred with 10 votes per share; appoints Dr. Radka Milanova to board","bullets":["Board designated 49.5M of 50M authorized preferred shares as Convertible Preferred Stock with 10 votes per share on as-converted basis.","Exchange ratio: 5 common shares for 1 preferred share; conversion ratio: 1 preferred share for 5 common shares.","Only common shares held by insiders (officers, directors) are eligible to exchange into the new preferred stock.","Dr. Radka Milanova (PhD, Organic Chemistry) appointed to fill board vacancy left by deceased Dr. Chen-Walden.","Dr. Milanova receives $5,000 in common stock per attended board/committee meeting; no cash compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015344","json":"https://secwatch.observer/filing/0001493152-24-015344.json","markdown":"https://secwatch.observer/filing/0001493152-24-015344.md","text":"https://secwatch.observer/filing/0001493152-24-015344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/0001493152-24-015344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T15:51:27.507665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d321fec077","claim":"Dr. Radka Milanova was elected as Director at BIOXYTRAN, INC.","evidence_excerpt":"Effective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/0001493152-24-015344-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}